Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT05101109
What this trial is testing

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumor
ABL Bio, Inc. 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05529316
What this trial is testing

Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Who this might be right for
Advanced Melanoma
Agenus Inc. 150
Testing effectiveness (Phase 2)Ended earlyNCT03829501
What this trial is testing

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Who this might be right for
Squamous Cell Carcinoma of Head and NeckNon-small Cell Lung CancerHepatocellular Carcinoma+9 more
Kymab Limited 222
Testing effectiveness (Phase 2)Ended earlyNCT03387111
What this trial is testing

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

Who this might be right for
Squamous Cell Carcinoma
ImmunityBio, Inc. 4
Not applicableLooking for participantsNCT04165798
What this trial is testing

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 1,065
Testing effectiveness (Phase 2)UnknownNCT05390528
What this trial is testing

A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma

Who this might be right for
Advanced TumorsLymphomaMetastatic Tumors
Shanghai Henlius Biotech 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT06061809
What this trial is testing

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Who this might be right for
Glioblastoma
ImmunityBio, Inc. 34
Not applicableLooking for participantsNCT06634199
What this trial is testing

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer Stage IIIPDL1 Gene Mutation
Fundación GECP 50
Large-scale testing (Phase 3)Study completedNCT02367781
What this trial is testing

Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Squamous Non-Small Cell Lung
Hoffmann-La Roche 723
Not applicableUnknownNCT06423144
What this trial is testing

PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 150
Testing effectiveness (Phase 2)Ended earlyNCT06558799
What this trial is testing

LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
NovoCure GmbH 31
Not applicableStudy completedNCT03748901
What this trial is testing

PD-L1 Expression in Japanese Renal Cell Carcinoma Patients

Who this might be right for
Renal Cell Carcinoma
Chugai Pharmaceutical 830
Testing effectiveness (Phase 2)Active Not RecruitingNCT05980000
What this trial is testing

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

Who this might be right for
Recurrent Head and Neck CancerRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Carcinoma+3 more
Washington University School of Medicine 37
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06938334
What this trial is testing

A First-in-human Clinical Trial Using a Gene Therapy With Patient's Own Stem Cells to Treat Early Type 1 Diabetes

Who this might be right for
Diabetes, Type I
Altheia Science 15
Testing effectiveness (Phase 2)Looking for participantsNCT07252739
What this trial is testing

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 140
Early research (Phase 1)Study completedNCT03620201
What this trial is testing

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+11 more
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Study completedNCT04305041
What this trial is testing

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 100
Testing effectiveness (Phase 2)Study completedNCT02129556
What this trial is testing

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 58
Not applicableStudy completedNCT03539965
What this trial is testing

Triple-negative Breast Cancer: a New Perspective on Biomarkers

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast Cancer
Instituto Nacional de Cancer, Brazil 239
Large-scale testing (Phase 3)Ended earlyNCT03024996
What this trial is testing

Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

Who this might be right for
Renal Cell Carcinoma
Hoffmann-La Roche 778
Next Page